A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B | Synapse
April 10, 2026Open Access
A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B
Key Points
The study aims to evaluate the effectiveness of pradefovir mesylate compared to tenofovir disoproxil fumarate in treating chronic hepatitis B.
Randomized, double-blind, phase 3 trial design
Comparison of pradefovir mesylate and tenofovir disoproxil fumarate
Conducted with Chinese patients diagnosed with chronic hepatitis B
Pradefovir mesylate showed comparable effectiveness to tenofovir disoproxil fumarate
Pradefovir should be regarded as a highly recommended treatment option for chronic hepatitis B patients
Abstract
Pradefovir should be a highly recommended treatment option for adult patients with CHB.